MedTrace Logo

Comparative Effects of Aspirin and NHP-544C

NCT02189122 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2016-07-12

Study results available
· View outcomes & findings →

Summary

The investigators will compare the effects of rapid release aspirin and NHP-544C on the prostacyclin response to intravenous bradykinin.

Conditions

  • Healthy

Interventions

DRUG

Bradykinin

Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.

DRUG

Aspirin 81 mg

Subjects will take Aspirin 81 mg per day for five days.

DRUG

Aspirin 162 mg

Subjects will take aspirin 162 mg per day for 5 days.

DRUG

NHP544-C 81 mg

Subjects will take NHP544C 81 mg per day for five days.

DRUG

NHP544C 162 mg

Subjects will take NHP544C 162 mg once a day for five days.

DRUG

Placebo

Subjects will take matching placebo for five days.

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Nancy J Brown, MD · Vanderbilt University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02189122 on ClinicalTrials.gov